Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 9 (5), 601-6

Infliximab Versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

Affiliations
Comparative Study

Infliximab Versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study

Eun Hye Kim et al. Gut Liver.

Abstract

Background/aims: In patients with corticosteroid-refractory ulcerative colitis (UC), cyclosporine or infliximab may be added to the treatment regimen to induce remission. Here, we aimed to compare the efficacy of cyclosporine and infliximab.

Methods: Between January 1995 and May 2012, the medical records of 43 patients with corticosteroid-refractory UC who received either infliximab or cyclosporine as a rescue therapy at a tertiary care hospital in Korea were reviewed.

Results: Among the 43 patients, 10 underwent rescue therapy with cyclosporine and the remaining 33 patients received infliximab. A follow-up of 12 months was completed for all patients. The colectomy rate at 12 months was 30% and 3% in the cyclosporine and the infliximab groups, respectively (p=0.034). However, the Cox proportional hazard model indicated that the treatment of rescue therapy was not an independent associate factor for preventing colectomy (p=0.164). In the subgroup analysis, infliximab with azathioprine was superior to cyclosporine for preventing colectomy (hazard ratio of infliximab with azathioprine compared with cyclosporine only, 0.073; 95% confidence interval, 0.008 to 0.629).

Conclusions: No difference between infliximab and cyclosporine with respect to preventing colectomy was noted. However, infliximab with azathioprine may be more effective than cyclosporine alone for preventing colectomy.

Keywords: Colitis, ulcerative; Cyclosporine; Infliximab.

Figures

Fig. 1
Fig. 1
Kaplan-Meier plots for colectomy-free survival according to the drug for rescue therapy.

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

References

    1. Gracie DJ, Ford AC. Evidence-based management of ulcerative colitis. Minerva Gastroenterol Dietol. 2012;58:87–99. - PubMed
    1. Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012;27:487–492. doi: 10.1111/j.1440-1746.2011.06958.x. - DOI - PubMed
    1. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010;4:431–437. doi: 10.1016/j.crohns.2010.02.001. - DOI - PubMed
    1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955;2:1041–1048. doi: 10.1136/bmj.2.4947.1041. - DOI - PMC - PubMed
    1. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–1070. doi: 10.1016/S0140-6736(74)90552-2. - DOI - PubMed

Publication types

MeSH terms

Feedback